TMDX — TransMedics Group, Inc. stock price, charts and financials

Latest market price

81.55

+5.04+6.59%

Overview Short InterestFilings

TMDXQT37TransMedics Group, Inc.·NASDAQ

Overview Short InterestFilings

81.55+6.59%

Earnings

Up 6.6% — Earnings due 2026-08-04 — pre-report positioning.

Medium confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

ESTA+0.28%$92.80 AXGN+8.34%$45.73 UFPT+5.00%$267.53 BFLY+15.61%$8.22 IRTC+6.39%$124.66 HAE+1.46%$86.79 NVCR+3.23%$15.32 ITGR+2.67%$124.45

Snapshot

Index	-	P/E	15.21	EPS (ttm)	5.03	Insider Own	4.83%	Shs Outstand	34.56M	Perf Week	5.88%

Market Cap	2.64B	Forward P/E	24.83	EPS next Y	3.08	Insider Trans	-1.47%	Shs Float	33.43M	Perf Month	12.76%

Enterprise Value	3.05B	PEG	0.06	EPS next Q	-	Inst Own	-	Short Float	23.08%	Perf Quarter	-24.09%

Income	172.93M	P/S	4.16	EPS this Y	-59.16%	Inst Trans	-	Short Ratio	5.77	Perf Half Y	-44.94%

Sales	635.89M	P/B	5.33	EPS next Y	72.69%	ROA	11.98%	Short Interest	7.72M	Perf YTD	-37.11%

Book/sh	-	P/C	11.95	EPS next 5Y	45.09%	ROE	41.92%	52W High	166.29 -50.96%	Perf Year	-28.96%

Cash/sh	-	P/FCF	17.47	EPS past 3/5Y	-	ROIC	6.94%	52W Low	64.07 27.28%	Perf 3Y	-16.33%

Dividend Est.	-	EV/EBITDA	21.80	Sales past 3/5Y	86.68% 87.65%	Gross Margin	59.09%	Volatility	4.45% 4.38%	Perf 5Y	158.48%

Dividend TTM	-	EV/Sales	4.79	EPS Y/Y TTM	332.67%	Oper. Margin	14.85%	ATR (14)	3.65	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	6.19	Sales Y/Y TTM	43.89%	Profit Margin	27.04%	RSI (14)	55.84	Recom	2.25

Dividend Gr. 3/5Y	-	Current Ratio	6.74	EPS Q/Q	-57.14%	SMA20	3.71%	Beta	1.91	Target Price	110.86

Payout	0.00%	Debt/Eq	1.75	Sales Q/Q	20.83%	SMA50	5.77%	Rel Volume	0.40	Prev Close	76.51

Employees	898	LT Debt/Eq	0.96	Earnings	Aug 04	SMA200	-29.88%	Avg Volume	1.31M	Price	81.55

IPO Date	May 02, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-49.85% -0.29%	Net Debt/EBITDA	2.87	Volume	532,335	Change	6.59%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-28-26	Initiated	UBS	Neutral	$80
Jul-06-26	Reiterated	Evercore ISI Group	Outperform	$155 → $90
Jun-18-26	Reiterated	Stifel Nicolaus		$75 → $80
May-26-26	Reiterated	Stifel Nicolaus		$85 → $75
May-06-26	Reiterated	Stifel Nicolaus		$130 → $85
May-06-26	Reiterated	Robert W. Baird		$157 → $140
May-06-26	Reiterated	Canaccord Genuity	Buy	$148 → $124
May-06-26	Reiterated	Needham	Buy	$166 → $142
May-06-26	Reiterated	Piper Sandler	Overweight	$140 → $120
Mar-09-26	Reiterated	Stifel Nicolaus		$115 → $130

Latest News

Jul-28-26

Jul-28-2604:29PM

TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conferenceprnewswire.com

11:06AM

Analysts Estimate TransMedics (TMDX) to Report a Decline in Earnings: What to Look Out forzacks.com

09:50AM

TransMedics Group (NASDAQ:TMDX): An Affordable Growth Stock With Strong Earnings MomentumChartMill

Jul-24-26

Jul-24-2602:25PM

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?prnewswire.com

Jul-21-26

Jul-21-2604:05PM

TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026prnewswire.com

03:53AM

TransMedics Group, Inc. $TMDX Shares Bought by Bessemer Group Inc.defenseworld.net

Jul-07-26

Jul-07-2601:45PM

TransMedics Completes PAD Aviation Investment to Expand in Europezacks.com

08:15AM

Strata Critical Medical: A Better Alternative To TransMedics In Organ Transplant Logisticsseekingalpha.com

Jul-06-26

Jul-06-2607:05AM

TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbHprnewswire.com

Jul-03-26

Jul-03-2611:15AM

Where Will TransMedics Group Stock Be in 10 Years?fool.com

Jul-02-26

Jul-02-2607:15PM

3 Growth Stocks to Buy on the Dipfool.com

Jun-30-26

Jun-30-2602:16PM

Reasons to Retain TransMedics Stock in Your Portfolio for Nowzacks.com

Jun-18-26

Jun-18-2608:40AM

Stifel Maintains Hold on TransMedics Group, Raises Price Target to $80Benzinga

Company

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	636	605	442	242	93	30	26	24	13
Cost of Goods Sold Incl. D&A	260	243	179	88	28	9	9	10	7
Gross Profit	376	363	262	154	65	21	17	14	6
Selling, General and Administrative Excl. Other	198	185	169	120	70	38	24	24	12
Research and Development	77	69	56	63	27	22	19	20	14
Other Operating Expense	6	0	0	0	0	1	0	-1	0
Operating Income	94	109	37	-29	-31	-39	-26	-30	-20
Interest Expense	16	14	14	11	4	4	4	4	2
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	12	13	13	13	-1	-1	2	0	-1
Net Income Before Taxes	89	108	36	-27	-36	-44	-29	-34	-24
Income Taxes	-83	-83	0	-2	0	0	0	0	0
Consolidated Net Income	171	190	35	-25	-36	-44	-29	-34	-24
Net Income From Continuing Operations	171	190	35	-25	-36	-44	-29	-34	-24
Net Income	171	190	35	-25	-36	-44	-29	-34	-24
EPS (Recurring)	5.03	5.60	1.07	-0.77	-1.23	-1.60	-1.16	-2.36	-1.23
EPS (Basic, Before Extraordinaries)	5.03	5.60	1.07	-0.77	-1.23	-1.60	-1.16	-2.36	-1.23
EPS (Diluted)	4.37	4.87	1.01	-0.77	-1.23	-1.60	-1.16	-2.36	-1.23
EBITDA	139	148	70	-8	-29	-38	-23	-28	-20
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	18.66	24.98	61.73	—	—	—	—	—	—
Price To Sales Ratio	4.36	6.84	4.66	10.76	19.91	17.88	19.13	11.09	—
Gross Margin	59.12	60.00	59.28	63.64	69.89	70.00	65.38	58.33	46.15
Operating Margin	14.78	18.02	8.37	-11.98	-33.33	-130.00	-100.00	-125.00	-153.85
Net Margin	26.89	31.40	7.92	-10.33	-38.71	-146.67	-111.54	-141.67	-184.62
Shares Outstanding	34	34	33	33	30	28	25	14	19
Market Capitalization	2,773	4,136	2,058	2,605	1,852	536	497	266	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gunderson Thomas J.	Director	Jun 15 '26	Sale	75.06	9,624	722,377	16,642	Jun 17
Gunderson Thomas J.	Director	Jun 15 '26	Option Exercise	2.21	19,285	42,620	26,266	Jun 17
Lovell Stephanie	Director	Mar 04 '26	Sale	149.62	1,193	178,497	2,866	Mar 06
Weill David	Director	Mar 04 '26	Option Exercise	14.20	3,571	50,708	15,705	Mar 06
Weill David	Director	Mar 04 '26	Sale	146.82	3,571	524,294	12,134	Mar 06
Hernandez Gerardo	Chief Financial Officer	Mar 04 '26	Option Exercise	71.17	7,236	515,001	20,601	Mar 04
Hernandez Gerardo	Chief Financial Officer	Mar 04 '26	Sale	147.21	5,912	870,306	14,689	Mar 04
Hernandez Gerardo	Chief Financial Officer	Mar 02 '26	Sale	139.12	375	52,170	14,689	Mar 04
Ranganath Anil P.	See remarks	Mar 02 '26	Sale	139.12	864	120,200	13,091	Mar 04
Corcoran Nicholas	See remarks	Mar 02 '26	Sale	139.12	2,966	412,630	29,831	Mar 04
Hernandez Gerardo	Chief Financial Officer	Dec 04 '25	Sale	139.62	920	128,450	15,064	Dec 05
Weill David	Director	Dec 03 '25	Sale	138.64	5,000	693,200	12,134	Dec 05
Weill David	Director	Dec 03 '25	Option Exercise	14.20	5,000	71,000	17,134	Dec 05
Ranganath Anil P.	See remarks	Nov 25 '25	Option Exercise	93.88	3,000	281,640	16,955	Nov 26
Ranganath Anil P.	See remarks	Nov 25 '25	Sale	145.22	3,000	435,660	13,955	Nov 26

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.